A Phase 3 interventional study of Tirzepatide Dose 1 and Tirzepatide Dose 2 in Type2 Diabetes, Diabetes Mellitus and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 51 sites in 9 countries. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company — 10 open to participants now, 21 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Eli Lilly and Company.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 144th largest by enrollment of the 232 interventional ones that give a count, is one of 11 that started in 2022, is one of 85 in phase 3, and was the 179th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →10 of the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Eli Lilly and Company · Sites in United States, China, Czechia and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
238 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 77 · Phase 2 37 · Phase 3 87 · Phase 4 33
First in 2001; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 181 across the 232 interventional studies, 677 across the 5 observational. Of the 211 that completed or were terminated, 155 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 of the studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT07215312Eli Lilly and CompanyA Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | 2026-11 |
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 99 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind: Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level
Drug: Tirzepatide Dose 1
Double-Blind: Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level
Drug: Tirzepatide Dose 2
Double-Blind: Participants receive placebo during the 30-week double-blind period. Open-Label: Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached.
Drug: Tirzepatide Dose 1 · Drug: Placebo
Administered SC
Administered SC
Administered SC
This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)
Time frame: Baseline, Week 30
Change From Baseline in HbA1c (Individual Doses)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
Time frame: Baseline, Week 30
Percentage of Participants Who Achieve ≤6.5% of HbA1c
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 30
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched)
BMI SDS (age and sex matched), calculated using the World Health Organization (WHO) growth reference standards. BMI is calculated as weight in kilograms divided by height in meters squared (kg/m²) and converted to a Z-score (SDS) based on WHO reference data. A Z-score of 0 represents the population mean for a given age and sex. A BMI SDS between -1 and +1 is considered normal. Obesity is defined as BMI SDS \> +2. Reductions in BMI SDS indicate improvement in weight status for individuals with obesity. LS mean was determined by the ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)
Time frame: Baseline, Week 30
Change From Baseline in Fasting Serum Glucose (FSG)
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
Time frame: Baseline, Week 30
Percent Change From Baseline in BMI
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
Time frame: Baseline, Week 30
Percentage of Participants Who Achieve <5.7% of HbA1c
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 30
Percentage of Participants Who Achieve <7.0% of HbA1c
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 30
Percent Change From Baseline for Serum Lipid Levels
Geometric LS mean was determined by the MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 30
Change From Baseline in Height Standard Deviation Score (SDS)
Height SDS (age and sex-matched), calculated using the World Health Organization (WHO) growth reference standards. Height SDS is derived by comparing a child's height to the median height for their age and sex in the WHO reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean. A Height SDS below -2 indicates short stature. Positive changes in Height SDS from baseline reflect improvement in growth velocity or catch-up growth. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured
Time frame: Baseline, Week 30
Change From Baseline in Weight SDS
Weight SDS, calculated using Centers for Disease Control and Prevention (CDC) growth reference standards. Weight SDS is derived by comparing a child's weight to median weight for their age and sex in the CDC reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean for a given age and sex. A Weight SDS below -2 may indicate underweight status, while a Weight SDS above +2 may indicate overweight or obesity. Change from baseline Weight SDS reflects shifts in growth trajectory, with positive changes indicating weight gain and negative changes indicating weight reduction. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured
Time frame: Baseline, Week 30
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children (ages 8 to 12) and teenagers (ages 13 to 18). The 23-item PedsQL Generic Core Scale includes physical, emotional, social, and school functioning dimensions. The PedsQL Generic Core yields two summary scores: Physical Summary and Psychosocial Summary. Scores are transformed on a 0-100 scale, with higher scores indicating better functioning. Each item is scored from 0 (never) to 4 (almost always). Items are reverse scored and linearly transformed to a 0-100 scale so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best). Higher scores indicate better health-related quality of life. LS mean was determined by the MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic Medication + Baseline Age Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured.
Time frame: Baseline, Week 52
Change From Baseline PedsQL (3.2) Diabetic Module
The PedsQL 3.2 Diabetes Module has 33 items for ages 13 years and older, and 32 items (1 less item for the Worry Scale) for ages 2 to 12 years. The 5 dimensions consist of diabetes symptoms (15 items), treatment barriers (5 items), treatment adherence (6 items), worry \[2 items (3 for teens and adults)\] and communication (4 items). Item scaling is a 5-point scale from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores reflect fewer problems and better functioning. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance- Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 52
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide
The steady-state AUCs were estimated from Tirzepatide concentrations at Weeks 0, 7, 16, and 29 using the population PK model by treatment group.
Time frame: Week 0: after the first dose anytime on the same day. Weeks 7, 16, and 29: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post-dose, as assigned by IWRS.
| Milestone | 5 Milligram (mg) Tirzepatide/5 mg Tirzepatide | 10 mg Tirzepatide/10 mg Tirzepatide | Placebo/5 mg Tirzepatide |
|---|---|---|---|
| Started | 32 | 33 | 34 |
| Received atleast one dose of study drug | 32 | 33 | 34 |
| Safety analysis set 1 | 32 | 33 | 34 |
| Completed | 29 | 29 | 32 |
| Not completed | 3 | 4 | 2 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal due to caregiver circumstances | 0 | 1 | 0 |
| Withdrew: Incorrectly enrolled | 0 | 1 | 0 |
| Milestone | 5 Milligram (mg) Tirzepatide/5 mg Tirzepatide | 10 mg Tirzepatide/10 mg Tirzepatide | Placebo/5 mg Tirzepatide |
|---|---|---|---|
| Started | 29 | 29 | 32 |
| Safety analysis set 2 | 32 | 33 | 32 |
| Completed | 29 | 29 | 32 |
| Not completed | 0 | 0 | 0 |
| Milestone | 5 Milligram (mg) Tirzepatide/5 mg Tirzepatide | 10 mg Tirzepatide/10 mg Tirzepatide | Placebo/5 mg Tirzepatide |
|---|---|---|---|
| Started | 29 | 29 | 32 |
| Completed | 29 | 29 | 32 |
| Not completed | 0 | 0 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)
| percentage of HbA1c | Pooled Doses of Tirzepatide (5 mg, 10 mg) | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) | -2.03 ± 0.165 | -0.23 ± 0.229 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
| percentage of HbA1c | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in HbA1c (Individual Doses) | -1.90 ± 0.236 | -2.16 ± 0.232 | -0.23 ± 0.229 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
| percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≤6.5% of HbA1c | 66.4 | 80.6 | 73.6 | 28.2 |
BMI SDS (age and sex matched), calculated using the World Health Organization (WHO) growth reference standards. BMI is calculated as weight in kilograms divided by height in meters squared (kg/m²) and converted to a Z-score (SDS) based on WHO reference data. A Z-score of 0 represents the population mean for a given age and sex. A BMI SDS between -1 and +1 is considered normal. Obesity is defined as BMI SDS \> +2. Reductions in BMI SDS indicate improvement in weight status for individuals with obesity. LS mean was determined by the ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)
| Z-score | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched) | -0.45 ± 0.072 | -0.76 ± 0.072 | -0.60 ± 0.050 | -0.09 ± 0.069 |
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
| milligram per deciliter (mg/dL) | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -35.5 ± 7.76 | -50.6 ± 7.40 | -43.0 ± 5.42 | -6.6 ± 7.36 |
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).
| Percent Change of BMI | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in BMI | -6.73 ± 1.155 | -11.07 ± 1.154 | -8.90 ± 0.808 | -0.55 ± 1.107 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
| percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieve <5.7% of HbA1c | 44.1 | 56.2 | 50.2 | 15.9 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
| percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieve <7.0% of HbA1c | 79.6 | 84.5 | 82.1 | 37.4 |
Geometric LS mean was determined by the MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change of Serum Lipid Levels | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Serum Cholesterol | -8.07 ± 2.319 | -13.82 ± 2.115 | -10.99 ± 1.564 | 5.07 ± 2.456 |
| Serum High-density lipoprotein (HDL) Cholesterol 3RD generation, enzymatic | 5.56 ± 3.269 | 1.72 ± 3.087 | 3.62 ± 2.247 | 0.92 ± 2.887 |
| Serum Triglycerides | -27.6 ± 4.816 | -35.8 ± 4.165 | -31.8 ± 3.165 | -1.74 ± 6.022 |
| Serum low-density lipoprotein (LDL) Cholesterol Combined | -6.08 ± 3.870 | -11.97 ± 3.540 | -9.07 ± 2.618 | 9.84 ± 4.185 |
| Serum very low-density lipoprotein (VLDL) Cholesterol Combined | -25.9 ± 5.005 | -34.8 ± 4.293 | -30.5 ± 3.276 | -0.26 ± 6.211 |
Height SDS (age and sex-matched), calculated using the World Health Organization (WHO) growth reference standards. Height SDS is derived by comparing a child's height to the median height for their age and sex in the WHO reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean. A Height SDS below -2 indicates short stature. Positive changes in Height SDS from baseline reflect improvement in growth velocity or catch-up growth. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured
| Z-score | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline in Height Standard Deviation Score (SDS) | -0.092 ± 0.0275 | -0.11 ± 0.0274 | -0.100 ± 0.0194 | -0.11 ± 0.0259 |
Weight SDS, calculated using Centers for Disease Control and Prevention (CDC) growth reference standards. Weight SDS is derived by comparing a child's weight to median weight for their age and sex in the CDC reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean for a given age and sex. A Weight SDS below -2 may indicate underweight status, while a Weight SDS above +2 may indicate overweight or obesity. Change from baseline Weight SDS reflects shifts in growth trajectory, with positive changes indicating weight gain and negative changes indicating weight reduction. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured
| Z-score | 5 mg Tirzepatide | 10 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline in Weight SDS | -0.38 ± 0.0600 | -0.50 ± 0.0594 | -0.44 ± 0.0422 | -0.099 ± 0.0570 |
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children (ages 8 to 12) and teenagers (ages 13 to 18). The 23-item PedsQL Generic Core Scale includes physical, emotional, social, and school functioning dimensions. The PedsQL Generic Core yields two summary scores: Physical Summary and Psychosocial Summary. Scores are transformed on a 0-100 scale, with higher scores indicating better functioning. Each item is scored from 0 (never) to 4 (almost always). Items are reverse scored and linearly transformed to a 0-100 scale so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best). Higher scores indicate better health-related quality of life. LS mean was determined by the MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic Medication + Baseline Age Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured.
| score on a scale | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo/5 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) |
|---|---|---|---|---|
| Physical Functioning Score | 4.26 ± 2.034 | 3.06 ± 2.092 | 5.03 ± 2.142 | 3.66 ± 1.456 |
| Emotional Functioning Score | 4.35 ± 3.506 | 4.11 ± 3.601 | 6.78 ± 3.705 | 4.23 ± 2.514 |
| Social Functioning Score | 4.16 ± 2.628 | 3.00 ± 2.696 | 4.54 ± 2.764 | 3.58 ± 1.878 |
| School Functioning Score | 13.30 ± 3.095 | 0.18 ± 3.152 | 12.03 ± 3.239 | 6.74 ± 2.197 |
| Psychosocial Health Summary Score | 7.82 ± 2.482 | 2.20 ± 2.533 | 7.47 ± 2.605 | 5.01 ± 1.767 |
| Physical Health Summary Score | 4.26 ± 2.034 | 3.06 ± 2.092 | 5.03 ± 2.142 | 3.66 ± 1.456 |
| Total Score | 6.65 ± 2.114 | 2.45 ± 2.163 | 6.61 ± 2.220 | 4.55 ± 1.507 |
The PedsQL 3.2 Diabetes Module has 33 items for ages 13 years and older, and 32 items (1 less item for the Worry Scale) for ages 2 to 12 years. The 5 dimensions consist of diabetes symptoms (15 items), treatment barriers (5 items), treatment adherence (6 items), worry \[2 items (3 for teens and adults)\] and communication (4 items). Item scaling is a 5-point scale from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores reflect fewer problems and better functioning. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance- Covariance structure (Change from Baseline) = Unstructured.
| score on a scale | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo/5 mg Tirzepatide | Pooled Doses of Tirzepatide (5mg,10mg) |
|---|---|---|---|---|
| Diabetes Management Summary Score | 7.21 ± 2.669 | 8.60 ± 2.733 | 5.25 ± 2.872 | 7.90 ± 1.907 |
| Total Score | 8.79 ± 2.310 | 8.74 ± 2.374 | 6.03 ± 2.489 | 8.76 ± 1.657 |
The steady-state AUCs were estimated from Tirzepatide concentrations at Weeks 0, 7, 16, and 29 using the population PK model by treatment group.
| nanogram*hour per milliliter (ng*hr/mL) | 5 mg Tirzepatide | 10 mg Tirzepatide |
|---|---|---|
| Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide | 92100 (85700 to 98600) | 184000 (171000 to 197000) |
Collected over Baseline Up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide / Double-Blind Period | 0/32 (0%) | 1/32 (3.1%) | 17/32 (53.1%) |
| TZP 10mg / Double-Blind Period | 0/33 (0%) | 1/33 (3%) | 19/33 (57.6%) |
| Placebo / Double-Blind Period | 0/34 (0%) | 1/34 (2.9%) | 11/34 (32.4%) |
| TZP 5mg / 5mg Open-Label and Safety Follow-Up Period | 0/32 (0%) | 1/32 (3.1%) | 10/32 (31.3%) |
| TZP 10mg / 10mg Open-Label and Safety Follow-Up Period | 0/33 (0%) | 1/33 (3%) | 7/33 (21.2%) |
| Placebo/TZP 5mg Open-Label and Safety Follow-Up Period | 0/32 (0%) | 0/32 (0%) | 8/32 (25%) |
| Event | 5 mg Tirzepatide / Double-Blind Period | TZP 10mg / Double-Blind Period | Placebo / Double-Blind Period | TZP 5mg / 5mg Open-Label and Safety Follow-Up Period | TZP 10mg / 10mg Open-Label and Safety Follow-Up Period | Placebo/TZP 5mg Open-Label and Safety Follow-Up Period |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 1/32 | 0/33 | 0/34 | 0/32 | 0/33 | 0/32 |
| CholecystitisHepatobiliary disorders | 0/32 | 0/33 | 0/34 | 1/32 | 0/33 | 0/32 |
| MastoiditisInfections and infestations | 0/32 | 1/33 | 0/34 | 0/32 | 0/33 | 0/32 |
| Suicide attemptPsychiatric disorders | 0/32 | 0/33 | 1/34 | 0/32 | 1/33 | 0/32 |
| DepressionPsychiatric disorders | 0/32 | 0/33 | 0/34 | 0/32 | 1/33 | 0/32 |
| Borderline personality disorderPsychiatric disorders | 0/32 | 0/33 | 1/34 | 0/32 | 0/33 | 0/32 |
| Suicidal ideationPsychiatric disorders | 0/32 | 0/33 | 1/34 | 0/32 | 0/33 | 0/32 |
| Event | 5 mg Tirzepatide / Double-Blind Period | TZP 10mg / Double-Blind Period | Placebo / Double-Blind Period | TZP 5mg / 5mg Open-Label and Safety Follow-Up Period | TZP 10mg / 10mg Open-Label and Safety Follow-Up Period | Placebo/TZP 5mg Open-Label and Safety Follow-Up Period |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/32 | 8/33 | 2/34 | 5/32 | 1/33 | 6/32 |
| NauseaGastrointestinal disorders | 7/32 | 6/33 | 3/34 | 2/32 | 0/33 | 0/32 |
| Abdominal painGastrointestinal disorders | 5/32 | 1/33 | 1/34 | 0/32 | 0/33 | 0/32 |
| VomitingGastrointestinal disorders | 5/32 | 4/33 | 1/34 | 1/32 | 2/33 | 1/32 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/32 | 0/33 | 5/34 | 0/32 | 0/33 | 0/32 |
| Abdominal pain upperGastrointestinal disorders | 2/32 | 4/33 | 3/34 | 0/32 | 0/33 | 0/32 |
| DyspepsiaGastrointestinal disorders | 2/32 | 4/33 | 0/34 | 0/32 | 0/33 | 0/32 |
| Decreased appetiteMetabolism and nutrition disorders | 0/32 | 4/33 | 0/34 | 0/32 | 0/33 | 0/32 |
| DysmenorrhoeaReproductive system and breast disorders | 0/21 | 0/18 | 0/21 | 2/21 | 0/18 | 0/20 |
| HeadacheNervous system disorders | 2/32 | 3/33 | 1/34 | 3/32 | 0/33 | 1/32 |
All randomized participants.
| Age, Continuous(years) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Mean | 15.00 ± 1.93 | 14.60 ± 1.83 | 14.60 ± 1.79 | 14.70 ± 1.84 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Female | 21 | 18 | 21 | 60 |
| Male | 11 | 15 | 13 | 39 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 24 | 17 | 24 | 65 |
| Not Hispanic or Latino | 8 | 16 | 9 | 33 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 5 | 8 | 20 |
| Asian | 1 | 2 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 3 |
| Black or African American | 5 | 4 | 2 | 11 |
| White | 17 | 19 | 21 | 57 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Australia | 1 | 1 | 0 | 2 |
| Brazil | 8 | 5 | 3 | 16 |
| India | 1 | 2 | 3 | 6 |
| Israel | 1 | 4 | 3 | 8 |
| Italy | 0 | 2 | 1 | 3 |
| Mexico | 10 | 8 | 13 | 31 |
| United Kingdom | 0 | 0 | 1 | 1 |
| United States | 11 | 11 | 10 | 32 |
| Hemoglobin A1c(Percentage of HbA1c) | 5 mg Tirzepatide | 10 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.22 ± 1.17 | 7.89 ± 1.22 | 8.02 ± 1.30 | 8.04 ± 1.23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in Jul 2024, 27 months.
Results were first posted in Sep 2025, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 27 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide